NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function
E. Mulvaney (Dublin, Ireland), F. Renzo (Dublin, Ireland), R. Adão (Porto, Portugal), G. Conceição (Porto, Portugal), E. Dupre (Sherbrooke, Canada), C. Laurent (Sherbrooke, Canada), P. Mendes-Ferreira (Porto, Portugal), C. Brás-Silva (Porto, Portugal), B. Kinsella (Dublin, Ireland)
Source: International Congress 2022 – Basic science in pulmonary hypertension
Session: Basic science in pulmonary hypertension
Session type: Thematic Poster
Number: 4140
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Mulvaney (Dublin, Ireland), F. Renzo (Dublin, Ireland), R. Adão (Porto, Portugal), G. Conceição (Porto, Portugal), E. Dupre (Sherbrooke, Canada), C. Laurent (Sherbrooke, Canada), P. Mendes-Ferreira (Porto, Portugal), C. Brás-Silva (Porto, Portugal), B. Kinsella (Dublin, Ireland). NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function. 4140
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|